조현병, 조현정동장애 외래 환자들의 대사증후군 유병률
Prevalence of the Metabolic Syndrome among Outpatients with Schizophrenia or Schizoaffective Disorder
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Objectives : The aim of this study were to assess a) the prevalence of metabolic syndrome in outpatients with schizophrenia or schizoaffective disorder, b) the comparison of characteristics of patients with or without the metabolic syndrome, c) the sensitivity, specificity and positive predictive values of individual criteria for metabolic syndrome. Methods : This study assessed the prevalence of the metabolic syndrome among 128 schizophrenia or schizoaffective disorder patients using the National Cholesterol Education Program-Adult Treatment Panel III. Results : Of patients, 54.7% (M : 49.3%, F : 61.4%) had metabolic syndrome. The metabolic syndrome was associated with medical history of diabetes, hypertension and dyslipidemia. Presence of abdominal obesity was most sensitive (97.1%), while raised fasting glucose was most specific (89.7%). Combining abdominal obesity/raised triglycerides and abdominal obesity/low HDL cholesterol had 100% sensitivity. Conclusion : The metabolic syndrome is highly prevalent among outpatients with schizophrenia or schizoaffective disorder. This study suggests that the measurement of abdominal obesity is a simple test to identify individuals at high risk for metabolic syndrome.
Abstract
Objectives : The aim of this study were to assess a) the prevalence of metabolic syndrome in outpatients with schizophrenia or schizoaffective disorder, b) the comparison of characteristics of patients with or without the metabolic syndrome, c) the sensitivity, specificity and positive predictive values of individual criteria for metabolic syndrome. Methods : This study assessed the prevalence of the metabolic syndrome among 128 schizophrenia or schizoaffective disorder patients using the National Cholesterol Education Program-Adult Treatment Panel III. Results : Of patients, 54.7% (M : 49.3%, F : 61.4%) had metabolic syndrome. The metabolic syndrome was associated with medical history of diabetes, hypertension and dyslipidemia. Presence of abdominal obesity was most sensitive (97.1%), while raised fasting glucose was most specific (89.7%). Combining abdominal obesity/raised triglycerides and abdominal obesity/low HDL cholesterol had 100% sensitivity. Conclusion : The metabolic syndrome is highly prevalent among outpatients with schizophrenia or schizoaffective disorder. This study suggests that the measurement of abdominal obesity is a simple test to identify individuals at high risk for metabolic syndrome.
참고문헌 (45)
- Lakka HM, "The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men", JAMA, 288, pp.2709~2716 (2002)
- Alberti KG, "Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation", Diabet Med, 15, pp.539~553 (1998)
- "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
- Alberti KG, "The metabolic syndrome--a new worldwide definition", Lancet, 366, pp.1059~1062 (2005)
- Brown S., "Excess mortality of schizophrenia. A meta-analysis", Br J Psychiatry, 171, pp.502~508 (1997)
- Curkendall SM, "Cardiovascular disease in patients with schizophrenia in Saskatchewan", Canada. J Clin Psychiatry, 65, pp.715~720 (2004)
- Hagg S, "High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia", Int Clin Psychopharmacol, 21, pp.93~98 (2006)
- Cohn T, "Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome", Can J Psychiatry, 49, pp.753~760 (2004)
- Dixon L, "The association of medical comorbidity in schizophrenia with poor physical and mental health", J Nerv Ment Dis, 187, pp.496~502 (1999)
- De Hert M, "Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE", Schizophr Res, 88, pp.222~226 (2006)
- Weiden PJ, "Obesity as a risk factor for antipsychotic noncompliance", Schizophr Res, 66, pp.51~57 (2004)
- Newcomer JW., "Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review", CNS Drugs, 19(Suppl 1), pp.1~93 (2005)
- Wirshing DA, "Schizophrenia and obesity: impact of antipsychotic medications", J Clin Psychiatry, 65(Suppl 18), pp.13~26 (2004)
- Newcomer JW, "Antipsychotic medications: metabolic and cardiovascular risk", J Clin Psychiatry, 68(Suppl 4), pp.8~13 (2007)
- Mukherjee S, "Family history of type 2 diabetes in schizophrenic patients", Lancet, 1, pp.495~ (1989)
- Ryan MC, "Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia", Am J Psychiatry, 160, pp.284~289 (2003)
- Spelman LM, "Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia", Diabet Med, 24, pp.481~485 (2007)
- Kahn RS, "Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial", Lancet, 371, pp.1085~1097 (2008)
- Scheen AJ, "Drug-induced diabetes mellitus: the exemple of atypical antipsychotics", Rev Med Liege, 60, pp.455~460 (2005)
- Scheen AJ, "Abnormal glucose metabolism in patients treated with antipsychotics", Diabetes Metab, 33, pp.169~175 (2007)
- McEvoy JP, "Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III", Schizophr Res, 80, pp.19~32 (2005)
- 남윤영, "만성 정신분열병 환자들의 대사증후군과 관련된 임상 특징들", 대한정신약물학회지, 17(4), pp.335~341 (2006), 대한정신약물학회
- Jeong JT, "Prevalence of Metabolic Syndrome in Chronic Schizophrenic Inpatients", Korean J Schizophr Res, 12, pp.83~89 (2009)
- 노재우, "정신분열병 입원 환자에서의 대사 증후군 유병률 연구", 생물정신의학, 18(1), pp.46~54 (2011), 대한생물정신의학회
- Lee NY, "Metabolic syndrome in patients with Schizophrenia and Bipolar disorder: comparision with general population", Abstracted presented at the Korea Neuropsychiatric Association Annual Meeting (2008)
- Sugawara N, "Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia", Ann Gen Psychiatry, 10, pp.21~29 (2011)
- Association AP, "Diagnostic and Statistical Manual of Mental Disorders( DSM-IV-TR). 4th evidence-based text revision ed" (2000), American Psychiatric Association
- Hales RE, "Text book of Psychiatry. 5 ed" (2008), American psychiatric publishing, Inc
- Panz VR, "Performance of the CardioChek PA and Cholestech LDX point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids", Cardiovasc J S Afr, 16, pp.112~117 (2005)
- World health organization, "The Asia-Pacific perspective: redefining obesity and its treatment. Februrary 2000. Health Communications" (2000), Australia PTY Ltd
- Mitchell AJ, "Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders--A Systematic Review and Meta-Analysis", Schizophr Bull (2011)
- Straker D, "Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications", Am J Psychiatry, 162, pp.1217~1221 (2005)
- Koponen HJ, "The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study", World J Biol Psychiatry, 11, pp.262~267 (2010)
- Kagal UA, "Prevalence of the Metabolic Syndrome in Schizophrenic Patients Receiving Second- Generation Antipsychotic Agents--A Cross-Sectional Study", J Pharm Pract (2012)
- Larsen JT, "Metabolic syndrome and psychiatrists’ choice of follow- up interventions in patients treated with atypical antipsychotics in Denmark and Sweden", Nord J Psychiatry, 65, pp.40~46 (2011)
- Nasrallah HA, "Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline", Schizophr Res, 86, pp.15~22 (2006)
- Bobes J, "Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort", Schizophr Res, 119, pp.101~109 (2010)
- Atmaca M, "Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics", J Clin Psychiatry, 64, pp.598~604 (2003)
- Pramyothin P, "Metabolic syndrome with the atypical antipsychotics", Curr Opin Endocrinol Diabetes Obes, 17, pp.460~466 (2010)
- De Hert MA, "Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication", Schizophr Res, 83, pp.87~93 (2006)
- Krane-Gartiser K, "Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics", Nord J Psychiatry, 65, pp.345~352 (2011)
- De Hert M, "Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study", Clin Pract Epidemiol Ment Health, 2, pp.14~23 (2006)
- Arango C, "A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study", Schizophr Res, 104, pp.1~12 (2008)
- Schorr SG, "The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year", J Psychiatr Res, 43, pp.1106~1111 (2009)
- Medved V, "Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up", J Psychopharmacol, 23, pp.915~922 (2009)